Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Study Title

A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia

Teva Identifier

TV44749-BA-10196

ClinicalTrials.gov Identifier

NCT06315283

Study Status

Recruiting

Trial Condition(s)

Schizophrenia

Interventions

Drug: TV-44749

EudraCT Number

2023-505664-11-00

Study Description

The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.
Click for participation criteria and map of study locations
CTIS Link

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 64 Years

Trial Duration

March 20, 2024 - April 18, 2025

Phase

Phase 1

Study Type

Interventional